Drug intelligence / Profile preview

varicella zoster virus modRNA

Development stage: Unknown
Lead developer: Pfizer
Modality: mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Varicella zoster virus modRNA (PF-07921186) is an investigational mRNA vaccine developed by Pfizer for the prevention of herpes zoster (shingles). The vaccine uses a modified RNA (modRNA) platform to encode antigens from the varicella zoster virus, aiming to stimulate an immune response that protects against shingles. It is administered intramuscularly as a suspension and is currently in Phase 2 clinical trials. The primary indication under investigation is herpes zoster in healthy adults[1][2][3][5].

Targets

Hla (Staphylococcus aureus alpha toxin)

Beyond the preview

Go deeper on varicella zoster virus modRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on varicella zoster virus modRNA.

Explore the full profile